Immuron announces first patients enrolled in travelan® clinical study

Highlights: first cohort of 30 healthy volunteers enrolled in the travelan® clinical trial clinical trial to examine a dosing regimen for travelan® more suited to the us military has commenced final 30 participants anticipated to be enrolled and commence the study in october 2023 travelan® is known to protect against the onset of travelers diarrhea (td), the most common illness reported by travelers melbourne, australia, july 25, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce the first cohort of 30 participants have been enrolled into the clinical trial to evaluate the efficacy of travelan® to prevent infectious diarrhea caused by enterotoxigenic escherichia coli (etec). the clinical study is being led by principal investigator dr mohamed al-ibrahim at the pharmaron cpc fda inspected clinical research facility inpatient unit located in baltimore, maryland us.
IMRN Ratings Summary
IMRN Quant Ranking